Targeting PAX2 for the treatment of breast cancer

Details for Australian Patent Application No. 2010286924 (hide)

Owner Phigenix, Inc.

Inventors Donald, Carlton D.

Agent Griffith Hack

Pub. Number AU-B-2010286924

PCT Pub. Number WO2011/025556

Priority 12/546,292 24.08.09 US; 12/708,294 18.02.10 US

Filing date 19 February 2010

Wipo publication date 3 March 2011

Acceptance publication date 9 August 2012

International Classifications

A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

A61P 35/00 Antineoplastic agents

C12N 15/113 Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

19 April 2012 PCT application entered the National Phase

  PCT publication WO2011/025556 Priority application(s): WO2011/025556

9 August 2012 Application Accepted

  Published as AU-B-2010286924

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010286926-Brush seal with stress and deflection accomodating membrane

2010286921-Method and system for integrated professional continuing education related services